scholarly journals Differential survival and therapy benefit of breast cancer patients are characterized by distinct epithelial and immune cell microenvironments

2021 ◽  
pp. clincanres.1442.2021
Author(s):  
Lennart Kester ◽  
Danielle Seinstra ◽  
Annelot G.J. van Rossum ◽  
Claire Vennin ◽  
Marlous Hoogstraat ◽  
...  
2014 ◽  
Vol 63 (4) ◽  
pp. 395-406 ◽  
Author(s):  
Shenyou Sun ◽  
Xiaochun Fei ◽  
Yan Mao ◽  
Xiumin Wang ◽  
David H. Garfield ◽  
...  

JCI Insight ◽  
2020 ◽  
Vol 5 (4) ◽  
Author(s):  
Claire E. Gustafson ◽  
Rohit Jadhav ◽  
Wenqiang Cao ◽  
Qian Qi ◽  
Mark Pegram ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 3450
Author(s):  
Debaditya Chakraborty ◽  
Cristina Ivan ◽  
Paola Amero ◽  
Maliha Khan ◽  
Cristian Rodriguez-Aguayo ◽  
...  

We investigated the data-driven relationship between immune cell composition in the tumor microenvironment (TME) and the ≥5-year survival rates of breast cancer patients using explainable artificial intelligence (XAI) models. We acquired TCGA breast invasive carcinoma data from the cbioPortal and retrieved immune cell composition estimates from bulk RNA sequencing data from TIMER2.0 based on EPIC, CIBERSORT, TIMER, and xCell computational methods. Novel insights derived from our XAI model showed that B cells, CD8+ T cells, M0 macrophages, and NK T cells are the most critical TME features for enhanced prognosis of breast cancer patients. Our XAI model also revealed the inflection points of these critical TME features, above or below which ≥5-year survival rates improve. Subsequently, we ascertained the conditional probabilities of ≥5-year survival under specific conditions inferred from the inflection points. In particular, the XAI models revealed that the B cell fraction (relative to all cells in a sample) exceeding 0.025, M0 macrophage fraction (relative to the total immune cell content) below 0.05, and NK T cell and CD8+ T cell fractions (based on cancer type-specific arbitrary units) above 0.075 and 0.25, respectively, in the TME could enhance the ≥5-year survival in breast cancer patients. The findings could lead to accurate clinical predictions and enhanced immunotherapies, and to the design of innovative strategies to reprogram the breast TME.


2021 ◽  
Vol 12 ◽  
Author(s):  
Qiang Liu ◽  
Yihang Qi ◽  
Jie Zhai ◽  
Xiangyi Kong ◽  
Xiangyu Wang ◽  
...  

Despite the promising impact of cancer immunotherapy targeting CTLA4 and PD1/PDL1, numerous cancer patients fail to respond. LAG3 (Lymphocyte Activating 3), also named CD233, serves as an alternative inhibitory receptor to be targeted in the clinic. The impacts of LAG3 on immune cell populations and coregulation of immune responses in breast cancer remain largely unknown. To characterize the role of LAG3 in breast cancer, we investigated transcriptome data and associated clinical information derived from 2,994 breast cancer patients. We estimated the landscape of the relationship between LAG3 and 10 types of cell populations of breast cancer. We investigated the correlation pattern between LAG3 and immune modulators in pancancer, particularly the synergistic role of LAG3 with other immune checkpoint members in breast cancer. LAG3 expression was closely related to the malignancy of breast cancer and may serve as a potential biomarker. LAG3 may play an important role in regulating the tumor immune microenvironment of T cells and other immune cells. More important, LAG3 may synergize with CTLA4, PD1/PDL1, and other immune checkpoints, thereby contributing more evidence to improve combination cancer immunotherapy by simultaneously targeting LAG3, PD1/PDL1, and CTLA4.


Author(s):  
Soraia Lobo-Martins ◽  
Patrícia Corredeira ◽  
Patrícia Borges Alves ◽  
Marília Antunes ◽  
Ângela Rodrigues ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document